Merus N.V. Files 2025 DEF 14A on Executive Compensation
| Field | Detail |
|---|---|
| Company | Merus N.V. |
| Form Type | DEF 14A |
| Filed Date | Apr 24, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, executive-compensation, corporate-governance
TL;DR
Merus N.V. DEF 14A out: exec pay & board details for FY24. Shareholders watch closely.
AI Summary
Merus N.V. filed a DEF 14A on April 24, 2025, detailing executive compensation and corporate governance matters for the fiscal year ending December 31, 2024. The filing includes compensation details for named executive officers and information regarding the company's board of directors and committees. Merus N.V. is a biopharmaceutical company focused on developing innovative cancer therapies.
Why It Matters
This filing provides transparency into how Merus N.V. compensates its top executives and outlines the structure of its board, which can influence strategic decisions and shareholder value.
Risk Assessment
Risk Level: medium — DEF 14A filings are routine but can reveal information about executive compensation and corporate governance that may impact investor confidence and stock price.
Key Numbers
- 2024 — Fiscal Year End (The filing covers executive compensation and corporate governance for this fiscal year.)
- 20250424 — Filing Date (Date the DEF 14A was submitted to the SEC.)
Key Players & Entities
- Merus N.V. (company) — Filer of the DEF 14A
- 0001193125-25-093505 (filing_id) — Accession number for the filing
- 20250424 (date) — Filing date
- 20250521 (date) — Period of report
- Yalelaan 62, 3584 CM Utrecht, DE (address) — Company's business and mailing address
FAQ
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, also known as a Definitive Proxy Statement, is used to solicit proxies from shareholders in connection with annual or special meetings of security holders. It provides detailed information about matters to be voted on, including executive compensation, director elections, and corporate governance.
When is the period of report for this Merus N.V. DEF 14A filing?
The period of report for this filing is May 21, 2025.
What is Merus N.V.'s Standard Industrial Classification (SIC) code?
Merus N.V.'s SIC code is 2834, which corresponds to Pharmaceutical Preparations.
What was Merus N.V.'s former company name?
Merus N.V.'s former company name was Merus B.V., with a date of name change on August 19, 2015.
Where is Merus N.V. headquartered?
Merus N.V. is headquartered at Yalelaan 62, 3584 CM Utrecht, DE.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 24, 2025 regarding Merus N.V..